COVID Vaccine Developer Announcements

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer Announcements

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
:: Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels
:: Expected to enroll 415 participants; interim results expected in Q3 2021
:: In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants
Press releases March 12 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Mar 12, 2021,
:: Data have demonstrated vaccine protects against COVID-19 related hospitalization and death in broad geographic regions, including those with variants of significant concern(1)
:: Available on not-for-profit basis for emergency pandemic use
:: Compatible with standard vaccine storage, distribution channels, enabling delivery to remote areas

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
March 11, 2021
:: Data have demonstrated vaccine protects against COVID-19 related hospitalization in broad geographic regions, including those with emerging variants1
:: Decision follows the European Medicines Agency recommendation of the J&J COVID-19 vaccine2
:: The Company aims to begin delivery of its vaccine to the EU in the second half of April and is committed to supply 200 million doses in 20213

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
Mar 11, 2021
:: 100% protection against severe disease
:: Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19
:: Efficacy against variants confirmed in U.K. and South Africa

Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
March 10, 2021
:: Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa